As research interest in small-molecule enzymatic inhibitors grows, understanding the translational status of novel compounds is critical for laboratory investigators. 5-Amino-1MQ functions as a selective inhibitor of Nicotinamide N-methyltransferase (NNMT), widely evaluated in cell lines and animal models for its role in cellular energy kinetics.
As research interest in small-molecule enzymatic inhibitors grows, understanding the translational status of novel compounds is critical for laboratory investigators. 5-Amino-1MQ functions as a selective inhibitor of Nicotinamide N-methyltransferase (NNMT), widely evaluated in cell lines and animal models for its role in cellular energy kinetics.
When evaluating the primary query regarding 5-amino-1mq human clinical trial safety nnmt inhibitor dynamics, it is essential to establish the precise status of the compound in scientific literature. Currently, robust, peer-reviewed human clinical trial safety data for 5-Amino-1MQ remains absent from clinical trial registries such as ClinicalTrials.gov. The overwhelming majority of available safety, pharmacokinetic, and pharmacodynamic data stems exclusively from preclinical rodent models and in vitro cell culture systems. Consequently, 5-Amino-1MQ is designated strictly as an investigational research chemical for laboratory use only and is not approved for human consumption, therapeutic use, or clinical administration.
In preclinical settings, research teams examining 5-amino-1mq human clinical trial safety surrogate markers focus heavily on cellular cytotoxicity assays, hepatic enzyme profiling, and systemic tolerability in mice. Studies utilizing high-fat diet-induced obesity mouse models demonstrated that targeted inhibition of NNMT via 5-Amino-1MQ did not produce acute toxicity, overt neurological distress, or adverse organ weight changes at tested experimental dosages. However, extrapolating preclinical safety observations to human clinical profiles requires rigorous phase I through phase III human trials, which have not yet been validated or published in controlled peer-reviewed clinical journals. Investigators utilizing 5-Amino-1MQ must maintain strict in vitro and animal laboratory protocols to gather further mechanistic insights.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme responsible for catalyzing the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). In metabolic tissue—particularly white adipose tissue (WAT) and liver tissue—elevated NNMT activity acts as a metabolic sink, draining available NAM and methyl donors. 5-Amino-1MQ was engineered specifically as a membrane-permeable, small-molecule inhibitor designed to dock into the catalytic pocket of NNMT, competitively blocking its enzymatic activity.
By inhibiting NNMT activity, 5-Amino-1MQ prevents the irreversible methyl-conjugation and subsequent renal excretion of nicotinamide. This enzymatic blockade allows nicotinamide to remain available within the cell, directly feeding back into the NAD+ salvage pathway. Through this precise mechanism, preclinical models have shown that NNMT inhibition restores intracellular nicotinamide adenine dinucleotide (NAD+) concentrations without relying on exogenous NAD+ precursor overload. Researchers studying NAD+ metabolic pathways frequently utilize 5-Amino-1MQ to map the upstream enzymatic regulation of cellular redox states.
The salvage pathway of NAD+ synthesis relies heavily on the conversion of nicotinamide to nicotinamide mononucleotide (NMN) via the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT). When NNMT is hyperactive, it competes directly with NAMPT for free nicotinamide. Preclinical evaluations demonstrate that applying an NNMT inhibitor like 5-Amino-1MQ effectively redirects nicotinamide back toward NAMPT-mediated conversion. This shift results in a measurable increase in intracellular NMN and subsequently elevated NAD+ pools.
Elevated intracellular NAD+ levels serve as a critical cofactor for poly(ADP-ribose) polymerases (PARPs) and sirtuins (specifically SIRT1 and SIRT3). Sirtuin activation plays a pivotal role in promoting mitochondrial biogenesis, regulating histone deacetylase activity, and optimizing cellular energy balance. In vitro assays using mature adipocytes and myotubes show that treatment with 5-Amino-1MQ increases the ratio of NAD+ to NADH, enhancing the biochemical environment required for efficient cellular respiration. Laboratory protocols involving the PX1 Research chemical library often examine these downstream enzymatic cascades to quantify cellular energy shifts.
Mitochondrial decay and diminished oxidative phosphorylation are hallmarks of cellular metabolic dysfunction. In vitro research using extracellular flux analyzers (such as Seahorse XF assays) has provided deep insights into how 5-Amino-1MQ alters cellular oxygen consumption rates (OCR) and extracellular acidification rates (ECAR). When NNMT is inhibited in cultured cell lines, researchers observe a significant increase in basal respiration, ATP-linked respiration, and maximal respiratory capacity.
This upregulation of mitochondrial output occurs alongside an increase in the expression of key mitochondrial proteins, including peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and uncoupling protein 1 (UCP1) in adipocytes. Rodent models administered 5-Amino-1MQ exhibited increased energy expenditure without alterations in total caloric intake, pointing toward an intrinsic shift in basal metabolic rate driven by uncoupled mitochondrial respiration. Understanding these respiratory shifts remains a core objective for laboratories investigating metabolic health, obesity dynamics, and mitochondrial dynamics.
NNMT expression is notably elevated in adipose tissue under conditions of nutrient excess and obesity. High NNMT activity correlates with reduced GLUT4 expression, impaired insulin signaling pathways, and decreased fatty acid oxidation within adipocytes. Preclinical studies involving diet-induced obese (DIO) mice treated with 5-Amino-1MQ demonstrated significant reductions in adipocyte volume and overall fat mass accumulation over multi-week experimental periods.
Crucially, in vitro data indicate that 5-Amino-1MQ induces a phenotypic shift in white adipocytes toward a brown-like (beige) phenotype, a process known as adipocyte browning. This transdifferentiation is characterized by increased mitochondrial density, elevated UCP1 expression, and enhanced lipolysis. Researchers analyzing lipid droplet dynamics in culture observe accelerated fatty acid mobilization and oxidation upon 5-Amino-1MQ administration, making it a foundational reference compound for studying lipid handling, metabolic flexibility, and adipose tissue remodeling.
To contextualize the experimental profile of 5-Amino-1MQ, researchers frequently compare its mechanisms against other prominent metabolic and mitochondrial research compounds. While 5-Amino-1MQ operates via direct small-molecule inhibition of NNMT within the cytosol, peptides like MOTS-c function as mitochondrial-derived peptides that translocate to the nucleus during metabolic stress to regulate genomic transcription. Conversely, fragment peptides such as AOD-9604 act primarily through lipolytic signaling pathways derived from human growth hormone domains without modulating the core NAD+ salvage pathway.
Furthermore, incretin mimetics like Semaglutide operate via GLP-1 receptor agonism to regulate central appetite networks and peripheral glucose-dependent insulin secretion. In contrast, 5-Amino-1MQ displays no binding affinity for peptide receptors such as GLP-1R or GH secretagogue receptors. Instead, it alters intracellular metabolic flux purely at the enzymatic level. Combining or contrasting these distinct mechanisms in comparative preclinical models provides researchers with comprehensive data regarding cell-autonomous versus endocrine-mediated metabolic modulation.
Assessing the in vitro safety and cytotoxicity profile of 5-Amino-1MQ is a primary step before conducting complex cellular assays. In standard cell culture viability assays (such as MTT or CCK-8 testing across HEK293, 3T3-L1, and C2C12 cell lines), 5-Amino-1MQ demonstrates low intrinsic cytotoxicity at micromolar working concentrations. Cell viability typically remains above 90% across standard acute exposure windows, provided concentrations do not exceed experimental thresholds.
In vivo rodent models evaluating tolerability parameters over 14-to-28-day periods reported no significant alterations in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), or creatinine levels. These biomarkers suggest that, within reported experimental dosage windows in mice, 5-Amino-1MQ does not induce immediate hepatic or renal damage. However, comprehensive pharmacokinetic profiling—including systemic half-life, plasma protein binding, cytochrome P450 inhibition profiles, and long-term toxicology studies—remains incomplete. Investigators must treat all literature findings as preliminary preclinical observations requiring careful scientific verification.
As a small-molecule quinoline derivative, 5-Amino-1MQ exhibits distinct solubility and physical stability characteristics compared to traditional linear peptides. In its lyophilized or solid powder form, 5-Amino-1MQ should be stored in a freezer at -20°C in a desiccated container protected from direct light exposure. Proper storage preserves compound integrity and prevents oxidative degradation over extended research timelines.
For reconstitution in laboratory workflows, 5-Amino-1MQ displays limited solubility in pure aqueous solutions or saline buffers. Optimal solubility is typically achieved using organic solvents such as dimethyl sulfoxide (DMSO) or ethanol, after which working dilutions can be prepared in cell culture media. Researchers should prepare fresh working aliquots to avoid repeated freeze-thaw cycles, which can induce precipitation or chemical decomposition. All handling must be conducted using appropriate personal protective equipment (PPE) inside a certified chemical fume hood or biosafety cabinet.
Due to the precise nature of enzymatic assays, laboratory outcomes depend entirely on the chemical purity and structural integrity of the compound. Impurities in small-molecule inhibitors can lead to off-target enzymatic binding, false-positive cytotoxicity, or irreproducible metabolic flux data. Therefore, sourcing 5-Amino-1MQ from verified domestic manufacturers that adhere to strict analytical quality controls is critical.
PX1 Research enforces rigorous quality assurance protocols for every lot of 5-Amino-1MQ distributed to academic and private research facilities. Every batch undergoes high-performance liquid chromatography (HPLC) to verify purity exceeding 99%, paired with mass spectrometry (MS) to confirm exact molecular mass and chemical identity. Furthermore, compounds undergo bacterial endotoxin testing (LAL assay) to ensure suitability for sensitive cell culture and in vivo applications. All analytical documentation is made available via comprehensive, lot-specific Certificates of Analysis (COAs) generated by ISO 17025-accredited laboratory partners.
Reliability in scientific research requires consistency across reagent procurement. PX1 Research synthesizes and processes its compound catalog within GMP-compliant, USA-based facilities, eliminating the purity variations and customs delays frequently associated with unverified overseas distributors. Researchers setting up a wholesale laboratory account benefit from predictable supply chains and fully documented analytical standards.
Orders placed through PX1 Research are fulfilled via same-day shipping (Monday through Friday) operating out of dual logistics hubs located in California and Arizona. This dual-coast infrastructure ensures rapid, temperature-monitored transit across the United States, minimizing cold-chain disruption risks during shipment. Laboratories working with critical timelines can rely on PX1 for verifiable, research-grade compounds supported by transparent batch tracking and dedicated technical support.
Has 5-Amino-1MQ undergone human clinical trials for safety?
No, formal peer-reviewed human clinical trial safety data for 5-Amino-1MQ has not been published or registered on clinical trial databases. Available research data is strictly derived from preclinical rodent models and in vitro cell culture studies. It is designated for laboratory research use only.
What is the primary enzymatic target of 5-Amino-1MQ?
5-Amino-1MQ is a selective, small-molecule inhibitor of Nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and regulates cellular NAD+ salvage pathways.
How does 5-Amino-1MQ influence cellular NAD+ levels in research models?
By inhibiting NNMT, 5-Amino-1MQ prevents the degradation of nicotinamide into 1-methylnicotinamide. This leaves more nicotinamide available for conversion into NAD+ via the NAMPT salvage pathway, elevating intracellular NAD+ pools in preclinical models.
What solvent should be used to reconstitute 5-Amino-1MQ powder?
5-Amino-1MQ is sparingly soluble in water but dissolves readily in organic solvents such as dimethyl sulfoxide (DMSO) or ethanol. Researchers typically dissolve the dry powder in DMSO before diluting into working assay media.
How should 5-Amino-1MQ be stored in the laboratory?
Solid, lyophilized 5-Amino-1MQ powder should be stored at -20°C in a dry, dark environment. Stock solutions dissolved in DMSO should be aliquoted and stored at -80°C to prevent freeze-thaw degradation.
How does PX1 Research verify the purity of 5-Amino-1MQ?
PX1 Research subjects every batch of 5-Amino-1MQ to independent third-party analysis by ISO 17025-accredited laboratories. Purity (>99%) and identity are verified via RP-HPLC and mass spectrometry, accompanied by LAL endotoxin testing.
What metabolic changes are observed in animal studies using 5-Amino-1MQ?
Preclinical studies in diet-induced obese mice show that 5-Amino-1MQ administration leads to increased basal metabolic rates, enhanced mitochondrial respiration, adipocyte size reduction, and elevated fat oxidation without changes in food intake.
Can 5-Amino-1MQ be compared to peptides like MOTS-c or AOD-9604?
Yes, while all three are studied in metabolic research contexts, their mechanisms differ completely. 5-Amino-1MQ is a small-molecule NNMT enzyme inhibitor, MOTS-c is a mitochondrial-derived signaling peptide, and AOD-9604 is a lipolytic growth hormone fragment peptide.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.